Company Description
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.
The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers.
SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 17, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 349 |
| CEO | Laura Francis |
Contact Details
Address: 471 El Camino Real, Suite 101 Santa Clara, California 95050 United States | |
| Phone | 408 207 0700 |
| Website | si-bone.com |
Stock Details
| Ticker Symbol | SIBN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001459839 |
| CUSIP Number | 825704109 |
| ISIN Number | US8257041090 |
| Employer ID | 26-2216351 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Laura A. Francis MBA | Chief Executive Officer and Director |
| Jeffrey W. Dunn | Executive Chairman |
| Anshul Maheshwari | Chief Financial Officer |
| Anthony J. Recupero | Advisor |
| Ashok Srinivasan B.E., M.Sc. | Vice President of Global Operations |
| Dr. Scott A. Yerby Ph.D. | Senior Vice President of Engineering and Chief Technology Officer |
| Saqib Iqbal | Vice President of Financial Planning and Analysis and Investor Relations |
| Michael A. Pisetsky J.D. | Chief Business and Legal Affairs Officer, Secretary and General Counsel |
| Nikolas F. Kerr | Chief Commercial Officer, SVice President of Product, Marketing and Business Development |
| Aimee Einstein | Vice President of People and Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 144 | Filing |